Guler, Sibel2024-06-122024-06-1220220161-64121743-1328https://doi.org/10.1080/01616412.2021.1967680https://hdl.handle.net/20.500.14551/22581Background In patients with multiple sclerosis (MS), the suboptimal response should be well evaluated at every step of treatment. Review Summary Determining patients with moderate or high activity and suboptimal response to treatment (clinical variables, MRI activity, perception of the patient and physician, side effects, serious risks, etc.) and timely intervention in the treatment are very important in achieving the desired effectiveness in the long term. Within the early stages, there is a limited time interval for effective treatment of MS patients. During this time, intervention is critical to achieve long-term positive results. After diagnosis, an early and individualized specific treatment for MS, depending on the severity of the disease, can prevent radiological and physical disability in the medium/long term. Conclusions With the emergence of a number of new treatments each with their own benefits and risks, a change in the nature of interactions between patients and MS physicians has been anticipated and will be required in the patient-related clinical decision-making process in the developing MS landscape.en10.1080/01616412.2021.1967680info:eu-repo/semantics/closedAccessMultiple SclerosisTreatment UnresponsivenessPrognosisIndividual Specific TreatmentTreatment FailureDisease-ActivityInterferon-BetaDisabilityRecommendationsProgressionGuidelinesArticle442177185Q3WOS:0006853350000012-s2.0-8511255308234396921Q2